Savara (NASDAQ: SVRA) reported Q2 EPS of ($0.16), $0.08 better than the analyst estimate of ($0.24).

“With a final design for IMPALA 2, we are working diligently on study preparations and expect it to start in the first quarter of next year,” said Rob Neville, Chief Executive Officer, Savara. “Building on the learnings from the first IMPALA study, and following constructive discussions with the regulatory agencies, we are confident in the study design and believe IMPALA 2 will effectively measure the potential efficacy and safety of Molgradex to treat aPAP.”

For earnings history and earnings-related data on Savara (SVRA) click here.